Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation
- Author
- CLEMENTS-JEWERY, Hugh1 ; HEARSE, David J1 ; CURTIS, Michael J1
[1] Cardiovascular Division, King's College London, London, United Kingdom - Source
British journal of pharmacology. 2005, Vol 145, Num 5, pp 551-564, 14 p ; ref : 3 p.3/4
- CODEN
- BJPCBM
- ISSN
- 0007-1188
- Scientific domain
- Pharmacology drugs
- Publisher
- Nature Publishing, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Acute myocardial infarction antiarrhythmic arrhythmia myocardial ischaemia phase 2 ventricular fibrillation proarrhythmia safety pharmacology sudden cardiac death
- Keyword (fr)
- Aigu Antiarythmique Cible Coeur Fibrillation ventriculaire Infarctus myocarde Ischémie myocarde Mort subite Recherche développement Sécurité Toxicité Traitement Trouble rythme cardiaque Appareil circulatoire pathologie Appareil circulatoire Cardiopathie coronaire Myocarde pathologie Trouble excitabilité Vaisseau sanguin pathologie
- Keyword (en)
- Acute Antiarrhythmic agent Target Heart Ventricular fibrillation Myocardial infarction Myocardial ischemia Sudden death Research and development Safety Toxicity Treatment Arrhythmia Cardiovascular disease Circulatory system Coronary heart disease Myocardial disease Excitability disorder Vascular disease
- Keyword (es)
- Agudo Antiarrítmico Blanco Corazón Fibrilación ventricular Infarto miocardio miocardio isquemia Muerte súbita Investigación desarrollo Seguridad Toxicidad Tratamiento Arritmia Aparato circulatorio patología Aparato circulatorio Cardiopatía coronaria Miocardio patología Trastorno excitabilidad Vaso sanguíneo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16933066
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjp.0706231 
https://dx.doi.org/10.1038/sj.bjp.0706231
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:9:\"\u0000*\u0000jtitle\";s:31:\"British journal of pharmacology\";s:9:\"\u0000*\u0000stitle\";s:16:\"Br. j. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:3:\"145\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"551\";s:8:\"\u0000*\u0000epage\";s:3:\"564\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1188\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:15:\"CLEMENTS-JEWERY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Hugh\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"HEARSE, David J\";i:1;s:17:\"CURTIS, Michael J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJPCBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:9:\"\u0000*\u0000jtitle\";s:31:\"British journal of pharmacology\";s:9:\"\u0000*\u0000stitle\";s:16:\"Br. j. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:3:\"145\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"551\";s:8:\"\u0000*\u0000epage\";s:3:\"564\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1188\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:15:\"CLEMENTS-JEWERY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Hugh\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"HEARSE, David J\";i:1;s:17:\"CURTIS, Michael J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJPCBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:9:\"\u0000*\u0000jtitle\";s:31:\"British journal of pharmacology\";s:9:\"\u0000*\u0000stitle\";s:16:\"Br. j. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:3:\"145\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"551\";s:8:\"\u0000*\u0000epage\";s:3:\"564\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1188\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:15:\"CLEMENTS-JEWERY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Hugh\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"HEARSE, David J\";i:1;s:17:\"CURTIS, Michael J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJPCBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:9:\"\u0000*\u0000jtitle\";s:31:\"British journal of pharmacology\";s:9:\"\u0000*\u0000stitle\";s:16:\"Br. j. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:3:\"145\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"551\";s:8:\"\u0000*\u0000epage\";s:3:\"564\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1188\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:15:\"CLEMENTS-JEWERY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Hugh\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"HEARSE, David J\";i:1;s:17:\"CURTIS, Michael J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJPCBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjp.0706231\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:9:\"\u0000*\u0000jtitle\";s:31:\"British journal of pharmacology\";s:9:\"\u0000*\u0000stitle\";s:16:\"Br. j. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:3:\"145\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"551\";s:8:\"\u0000*\u0000epage\";s:3:\"564\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1188\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:15:\"CLEMENTS-JEWERY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Hugh\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"HEARSE, David J\";i:1;s:17:\"CURTIS, Michael J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJPCBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Phase 2 ventricular arrhythmias in acute myocardial infarction : a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
